---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-004974"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:40:29.182172+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Tonix Pharmaceuticals Presents Positive Preclinical Data on TNX-1700 for Gastric Cancer at AACR 2025

## Summary
- At AACR 2025, Tonix showed TFF2-MSA (murine TNX-1700) plus anti-PD1 inhibited gastric tumor growth by 78.29% in mouse models.
- Combination therapy activated cancer-killing CD8+ T cells and reduced immunosuppressive PMN-MDSCs in the tumor microenvironment.
- TNX-1700 (hTFF2-HAS) is in preclinical development for gastric and colorectal cancers, with further studies planned.
- Data demonstrated TFF2-MSA outperformed CXCR4 antagonist AMD3100 in reducing PMN-MDSC generation.
- TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, supporting the therapeutic target.

## SEC filing metadata
- accession: 0001999371-25-004974
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/0001999371-25-004974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/tnxp-8k_042925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-004974
- JSON: https://secwatch.observer/filing/0001999371-25-004974.json
- Plain text: https://secwatch.observer/filing/0001999371-25-004974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.